CD163 and neoplasm: Heterogeneity of TAM phenotype was described in different tumour types [31] and at different locations of the same tumour [32, 33] e.g. in colon cancer patients, CD80+, CD86+ and HLA-DR+ [34], as well as CD163+, CD86+, CCR2+ cells were described [7].